2,388 research outputs found

    A double molecular disc in the triple-barred starburst galaxy NGC 6946: structure and stability

    Get PDF
    The late-type spiral galaxy NGC 6946 is a prime example of molecular gas dynamics driven by "bars within bars". Here we use data from the BIMA SONG and HERACLES surveys to analyse the structure and stability of its molecular disc. Our radial profiles exhibit a clear transition at distance R ~ 1 kpc from the galaxy centre. In particular, the surface density profile breaks at R ~ 0.8 kpc and is well fitted by a double exponential distribution with scale lengths R_1 ~ 200 pc and R_2 ~ 3 kpc, while the 1D velocity dispersion sigma decreases steeply in the central kpc and is approximately constant at larger radii. The fact that we derive and use the full radial profile of sigma rather than a constant value is perhaps the most novel feature of our stability analysis. We show that the profile of the Q stability parameter traced by CO emission is remarkably flat and well above unity, while the characteristic instability wavelength exhibits clear signatures of the nuclear starburst and inner bar within bar. We also show that CO-dark molecular gas, stars and other factors can play a significant role in the stability scenario of NGC 6946. Our results provide strong evidence that gravitational instability, radial inflow and disc heating have driven the formation of the inner structures and the dynamics of molecular gas in the central kpc.Comment: MNRAS, in pres

    Periodic orbits of period 3 in the disc

    Full text link
    Let f be an orientation preserving homeomorphism of the disc D2 which possesses a periodic point of period 3. Then either f is isotopic, relative the periodic orbit, to a homeomorphism g which is conjugate to a rotation by 2 pi /3 or 4 pi /3, or f has a periodic point of least period n for each n in N*.Comment: 7 page

    Particle dynamics inside shocks in Hamilton-Jacobi equations

    Full text link
    Characteristics of a Hamilton-Jacobi equation can be seen as action minimizing trajectories of fluid particles. For nonsmooth "viscosity" solutions, which give rise to discontinuous velocity fields, this description is usually pursued only up to the moment when trajectories hit a shock and cease to minimize the Lagrangian action. In this paper we show that for any convex Hamiltonian there exists a uniquely defined canonical global nonsmooth coalescing flow that extends particle trajectories and determines dynamics inside the shocks. We also provide a variational description of the corresponding effective velocity field inside shocks, and discuss relation to the "dissipative anomaly" in the limit of vanishing viscosity.Comment: 15 pages, no figures; to appear in Philos. Trans. R. Soc. series

    Patent foramen ovale and neurosurgery in sitting position: a systematic review

    Get PDF
    We have conducted a systematic review of air embolism complications of neurosurgery in the sitting position and patent foramen ovale (PFO) closure. It assesses the risk and benefit of PFO closure before neurosurgery in the sitting position. The databases Medline, Embase, and Cochrane Controlled Trial Register were systematically searched from inception to November 2007 for keywords in both topics separately. In total, 4806 patients were considered for neurosurgery in sitting position and 5416 patients underwent percutaneous PFO closure. The overall rate of venous air embolism during neurosurgery in sitting position was 39% for posterior fossa surgery and 12% for cervical surgery. The rate of clinical and transoesophageal echocardiography detected paradoxical air embolism was reported between 0% and 14%. The overall success rate for PFO closure using new and the most common closure devices was reported 99%, whereas the average risk of major complications is <1%. On the basis of our systematic review, we recommend screening for PFO and considering closure in cases in which the sitting position is the preferred neurosurgical approach. Our proposed management including the time of PFO closure according to available data is presented. However, the conclusions from our systematic review may be limited due to the lack of level A evidence and from using data from observational cohort studies. Thus, definite evidence-based recommendations require prospective evaluation of the issue in well-designed studie

    Topological Entropy of Braids on the Torus

    Full text link
    A fast method is presented for computing the topological entropy of braids on the torus. This work is motivated by the need to analyze large braids when studying two-dimensional flows via the braiding of a large number of particle trajectories. Our approach is a generalization of Moussafir's technique for braids on the sphere. Previous methods for computing topological entropies include the Bestvina--Handel train-track algorithm and matrix representations of the braid group. However, the Bestvina--Handel algorithm quickly becomes computationally intractable for large braid words, and matrix methods give only lower bounds, which are often poor for large braids. Our method is computationally fast and appears to give exponential convergence towards the exact entropy. As an illustration we apply our approach to the braiding of both periodic and aperiodic trajectories in the sine flow. The efficiency of the method allows us to explore how much extra information about flow entropy is encoded in the braid as the number of trajectories becomes large.Comment: 19 pages, 44 figures. SIAM journal styl

    Association of interleukin-1 gene cluster polymorphisms and haplotypes with multiple sclerosis in an Iranian population

    No full text
    Multiple sclerosis (MS) is a multi-factorial autoimmune disease of the central nervous system. The exact etiology of MS is still unknown. Due to the important roles that cytokines play as mediators in immune and inflammatory responses, we have evaluated the association of IL-1 gene cluster polymorphisms and haplotypes with MS susceptibility in 306 unrelated MS patients and 312 healthy matched controls. A significant association was found for the IL-1β + 3953 T allele [OR = 1.43, 95% CI (1.14-1.79), P value = 0.002, Pc= 0.01] and for IL-1β + 3953 T/T genotype and MS risk [OR = 1.92, 95% CI (1.25-2.96), P value = 0.005, Pc= 0.01]. Interestingly, the genotypes of the polymorphisms remained significant under recessive, co-recessive and dominant models. However, no significant differences were found between MS patients and controls in the genotype and allele frequencies of the IL-1β - 511, - 31 and IL-1Ra polymorphisms. Haplotype analysis for IL-1β - 31 and IL-1β - 511, with moderate linkage disequilibrium (LD), using the EM algorithm revealed a significant global association of haplotype differences between the two groups. Lower presence of two haplotypes (H3: C-T and H4: T-C) was observed in the MS patients than healthy controls. However, after applying Bonferroni's correction the differences were not significant. To our knowledge, this is the first study reporting the association of the IL-1β + 3953 gene polymorphism and MS susceptibility. © 2015 Elsevier B.V

    Bimodal release ondansetron for acute gastroenteritis among adolescents and adults: A randomized clinical trial

    Get PDF
    Importance: Vomiting resulting from acute gastroenteritis is commonly treated with intravenous antiemetics in acute care settings. If oral treatment were beneficial, patients might not need intravenous administered hydration or medication. Furthermore, a long-acting treatment could provide sustained relief from nausea and vomiting. Objective: To determine whether an experimental long-acting bimodal release ondansetron tablet decreases gastroenteritis-related vomiting and eliminates the need for intravenous therapy for 24 hours after administration. Design, Setting, and Participants: This placebo-controlled, double-blind, randomized clinical trial included patients from 19 emergency departments and 2 urgent care centers in the United States from December 8, 2014, to February 17, 2017. Patients 12 years and older with at least 2 vomiting episodes from presumed gastroenteritis in the previous 4 hours and symptoms with less than 36 hours\u27 duration were randomized using a 3:2 active to placebo ratio. Analyses were performed on an intent-to-treat basis and conducted from June 1, 2017, to November 1, 2017. Intervention: Bimodal release ondansetron tablet containing 6 mg of immediate release ondansetron and 18 mg of a 24-hour release matrix for a total of 24 mg of ondansetron. Main Outcomes and Measures: Treatment success was defined as no further vomiting, no need for rescue medication, and no intravenous hydration for 24 hours after bimodal release ondansetron administration. Results: Analysis included 321 patients (mean [SD] age, 29.0 [11.1] years; 195 [60.7%] women), with 192 patients in the bimodal release ondansetron group and 129 patients in the placebo group. Treatment successes were observed in 126 patients in the bimodal release ondansetron group (65.6%) compared with 70 patients in the placebo group (54.3%), with an 11.4% (95% CI, 0.3%-22.4%) absolute probability difference. The proportion of treatment success was 21% higher among patients who received bimodal release ondansetron compared with those who received a placebo (relative risk, 1.21; 95% CI, 1.00-1.46; P = .04). In an analysis including only patients with a discharge diagnosis of acute gastroenteritis and no major protocol violations, there were 123 treatment successes (69.5%) in the bimodal release ondansetron group compared with 67 treatment successes (54.9%) in the placebo group (relative risk, 1.27; 95% CI, 1.05-1.53; P = .01). Adverse effects were infrequent and similar to the known safety profile of ondansetron. Conclusions and Relevance: This randomized clinical trial found that a long-acting bimodal release oral ondansetron tablet was an effective antiemetic among adolescents and adults with moderate to severe vomiting from acute gastroenteritis. The drug benefits extended to 24 hours after administration. Bimodal release ondansetron may decrease the need for intravenous access and emergency department care to manage acute gastroenteritis. Trial Registration: ClinicalTrials.gov identifier: NCT02246439
    corecore